INVESTORS

Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate.  Regulus is advancing programs in renal and hepatic diseases. Regulus maintains its corporate headquarters in La Jolla, CA.